Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.3%

3 terminated/withdrawn out of 36 trials

Success Rate

87.0%

+0.5% vs industry average

Late-Stage Pipeline

17%

6 trials in Phase 3/4

Results Transparency

25%

5 of 20 completed trials have results

Key Signals

4 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

10(41.7%)

Phase 3

6(25.0%)

Phase 1

6(25.0%)

N/A

2(8.3%)

24Total

Phase 2(10)

Phase 3(6)

Phase 1(6)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials

NCT06844487Phase 3Active Not Recruiting

Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT05993442Not ApplicableRecruiting

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.

Role: lead

NCT04648280Phase 1Active Not Recruiting

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

Role: lead

NCT06139796Phase 1Withdrawn

Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV

Role: lead

NCT05993767Phase 2Completed

UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children

Role: lead

NCT04337450Phase 2Active Not Recruiting

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

Role: lead

NCT06844500Phase 3Active Not Recruiting

Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT03915366Phase 2Completed

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

Role: collaborator

NCT05965427Completed

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

Role: collaborator

NCT04301154Phase 1Completed

Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Role: collaborator

NCT02259127Phase 2Completed

ODYSSEY (PENTA 20)

Role: lead

NCT06873633Phase 2Recruiting

Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV

Role: lead

NCT07041190Phase 3Not Yet Recruiting

Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.

Role: lead

NCT04781530Not ApplicableCompleted

Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms

Role: lead

NCT06482151Withdrawn

Evaluation of the Prevalence of E. Coli O Serotypes in Paediatric Population With Recurrent Urinary Tract Infection

Role: lead

NCT05222139Completed

Monitoring COVID-19 Vaccination Response in Fragile Populations

Role: collaborator

NCT00825929Recruiting

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.